FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to methods of treating behavioral changes. A method for treating behavioral change in a patient includes administering to the patient a therapeutically effective amount of a KDM1A inhibitor, wherein the behavioral change in the individual is social withdrawal or aggressiveness. Also the use of a KDM1A inhibitor for the treatment of behavior change and for the manufacture of a medicinal product for the treatment of behavior change is disclosed, where the behavior change in a person is social withdrawal or aggressiveness.
EFFECT: group of inventions provides treatment of behavioral changes without any sedative effect.
18 cl, 6 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2010 |
|
RU2602814C2 |
| LYSINE-SPECIFIC HISTONE DEMETHYLASE 1A (KDM1A) INHIBITORS FOR DISEASE THERAPY | 2019 |
|
RU2813145C2 |
| FLUORINATED COMPOUND OF CYCLOPROPYLAMINE, THE METHOD OF PREPARATION, THE PHARMACEUTICAL COMPOSITION AND ITS USE | 2017 |
|
RU2746323C2 |
| NOVEL CYCLIN-DEPENDENT KINASE CDK9 INHIBITOR | 2018 |
|
RU2738654C1 |
| DERIVATIVES OF OXOPIPERIDINE, THEIR PRODUCTION AND USE IN THERAPY | 2005 |
|
RU2376298C2 |
| N-PHENYL(PIPERIDINE-2-YL)METHYL-BENZAMIDE DERIVATIVES, AND THEIR APPLICATION IN THERAPY | 2004 |
|
RU2351588C2 |
| PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF | 2016 |
|
RU2735522C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
